Skip to main content
Premium Trial:

Request an Annual Quote

Clarified Precision Medicine, VieCure Partner to Make Precision Oncology Expertise More Accessible

NEW YORK – Clarified Precision Medicine on Wednesday said it is partnering with healthcare technology firm VieCure to make it easier for oncologists to access expert interpretations of molecular profiling tests performed on their patients.

Clarified Precision Medicine employs a team of experts including medical oncologists, oncology pharmacists, data integration experts, and molecular pathologists, who consult with doctors in community, academic, and integrated health system practices and help them integrate the results of somatic and germline genetic tests into their patients' treatment plans. VieCure operates an artificial intelligence informatics software platform, which can also help oncologists develop precision treatment plans via a clinical inference engine and point-of-care decision support system.

In this partnership, VieCure will integrate Clarified's somatic and germline clinical consultation process within its AI platform so oncologists have easier, streamlined access to Clarified's expert team. In partnering with VieCure, Clarified hopes to make precision oncology expertise accessible via clinical decision support, similar to how tax experts are now available on demand to individuals through tax filing software, Howard McLeod, a nationally recognized precision medicine expert and managing director at Clarified, said in a statement.

Oncologists using VieCure's clinical decision support platform will be able to order molecular profiling tests for their patients. Within 48 hours of receiving results, a Clarified precision oncology expert will review the findings and provide a ranked list of treatment options, clinical trials, and other tests that may be needed.

The tie-up between VieCure and Clarified will also facilitate payor services. Insurers can use VieCure's platform to request a third-party clinical review from Clarified's experts to help decide whether to grant a prior authorization or reimburse a specific precision oncology intervention.